Clinical and pharmacological group: & nbsp

Means that inhibit the formation and promote the dissolution of concrements

Included in the formulation
  • Uralit-U®
    granules inwards 
    Madaus, GmbH     Germany
  • АТХ:

    G.04.B.C   Drugs for the treatment of nephrourolythiasis

    Pharmacodynamics:

    Dissolution and prevention of the formation of uric acid stones. It regulates the pH of the urine and permanently supports the shift of the reaction in the alkaline side to pH 6.2-7.5, at which the salts of uric acid are in solution and do not form concretes.

    Pharmacokinetics:

    Not studied.

    Indications:Urine stones (prevention and treatment), nefrourolitiaz and cystinuria (ancillary therapy); alkalinization of urine with porphyria of skin, uricosuria, treatment with cytostatics.

    IV.E70-E90.E72   Other disorders of amino acid metabolism

    IV.E70-E90.E80.2   Other porphyria

    XIV.N20-N23   Urolithiasis disease

    Contraindications:

    Acute and chronic renal failure, absolute prohibition on the use of table salt, severe disturbances of the acid-base state (metabolic alkalosis), chronic infections of the urinary tract.

    Carefully:

    No data.

    Pregnancy and lactation:Adequate and well-controlled studies in humans and animals have not been conducted. There is no information on the penetration into breast milk.

    Action category for the fetus by FDA - AT.

    Dosing and Administration:

    Inside, after meal.

    Daily dose (10 g) in 3 divided doses: in the morning and after dinner - 2.5 g (1 scoop), in the evening - 5 g (2 measuring spoons). This dose should provide an increase in the pH of fresh urine (isolated immediately before taking the next dose) to the following values: with uric acid stones - 6.2-6.8; with cystine stones - 7.5-8.5; at a cytostatic therapy - not less than 7; at a late porphyria of a skin - 7,2-7,5.

    If necessary, the daily dose is increased by adding 0.5 tablespoons of granules to the evening dose, or reduce, reducing the evening dose. The duration of therapy is 1-6 months.

    Side effects:

    Dyspepsia; phosphate nefrourolithiasis.

    Overdose:

    Not described.

    Interaction:

    Co-administration with drugs containing citrate and aluminum ion may cause increased resorption of aluminum. Take the last is necessary with an interval of at least 2 hours.

    Special instructions:

    It should be borne in mind that the average daily dose of the drug contains 1.72 g (44 mmol) of potassium ions, 1 g (44 mmol) of sodium ions.

    In the process of treatment with the drug, the patient should enter in the diary the amount of granules used and the urine pH values ​​collected immediately before taking the drug.

    Instructions
    Up